All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
VivoCAR™ Anti-ERBB2 (F5) h(CD28-41BB-CD3z) CAR circRNA utilizes the F5 ScFv to enable precision targeting of HER2-positive tumors through direct in vivo induction. The F5 clone is significant for its non-competing epitope binding, allowing it to function effectively in patients who have previously received Trastuzumab. By employing the circRNA platform, this product ensures a self-limiting therapeutic window that is vital for safely targeting ERBB2, protecting vital organs from long-term toxicity while providing a potent, non-viral method for the destruction of breast and ovarian cancer cells.
There are currently no customer reviews or questions for VivoCAR™ Anti-ERBB2 (F5) h(CD28-41BB-CD3z) CAR circRNA (XS-1225-YX35). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION